BioWorld MedTech

Oct. 5, 2018

Guardant prices $237.5M IPO above range, trades up almost 70 percent

It's not easy to pull off a major med-tech IPO, particularly for a diagnostics company. But Guardant Health Inc., which has staked a claim to being the leading liquid biopsy player, has priced its IPO to raise $237.5 million. Read More

Rare disease therapies delayed are promises broken, lives lost

Cambridge researcher planning to market artificial pancreas-related product

Medtronic launches Infinity OCT spinal system, sheds additional light on Mazor buy

Three win Chemistry Nobels for protein engineering methods

Other news to note

Daily M&A

Appointments and advancements

Financings

Product briefs

BioWorld MedTech's Diagnostics Extra

Today's news in brief

BioWorld

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...

Illustration of cancer cell in crosshairs being destroyed

RX-10616 improves radiotherapy efficacy in HNSCC

BioWorld Science

Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...